Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Product Segment
1.1.1.2. Application Segment
1.1.1.3. Technology Segment
1.1.1.4. End-use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.3.1. Objectives
1.3.2. Objective – 1
1.3.3. Objective – 2
1.3.4. Objective – 3
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information or Data Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Validation
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Product and Technology Snapshot
2.3. Application and End-use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Number of Government Initiatives
3.2.1.2. Growing Need for Rapid Detection of Diseases
3.2.1.3. Rising Prevalence of Chronic Infectious and Non-Infectious Diseases
3.2.1.4. Growing Awareness About Rapid Diagnostic Tests
3.2.2. Market Restraint Analysis
3.2.2.1. Advent of Advanced Techniques Such as PCR and Molecular Diagnostics
3.2.2.2. Frequent Product Recalls
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Rapid Medical Diagnostic Kits Market: Product Movement Analysis
4.2. OTC RDT
4.2.1. OTC RDT Market, 2018 – 2030 (USD Million)
4.3. Professional RDT
4.3.1. Professional RDT Market, 2018 – 2030 (USD Million)
Chapter 5. Technology Business Analysis
5.1. Rapid Medical Diagnostic Kits Market: Technology Movement Analysis
5.2. Lateral Flow
5.2.1. Lateral Flow Market, 2018 – 2030 (USD Million)
5.3. Agglutination
5.3.1. Agglutination Market, 2018 – 2030 (USD Million)
5.4. Solid Phase
5.4.1. Solid Phase Market, 2018 – 2030 (USD Million)
5.4.2. Agglutination Market, 2018 – 2030 (USD Million)
5.5. Other Technologies
5.5.1. Other Technologies Market, 2018 – 2030 (USD Million)
Chapter 6. Application Business Analysis
6.1. Rapid Medical Diagnostic Kits Market: Application Movement Analysis
6.2. Blood Glucose Testing
6.2.1. Blood Glucose Testing Market, 2018 – 2030 (USD Million)
6.3. Infectious Disease Testing
6.3.1. Infectious Disease Testing Market, 2018 – 2030 (USD Million)
6.4. Cardiometabolic Testing
6.4.1. Cardiometabolic Testing Market, 2018 – 2030 (USD Million)
6.5. Pregnancy and Fertility Testing
6.5.1. Pregnancy and Fertility Testing Market, 2018 – 2030 (USD Million)
6.6. Fecal Occult Blood Testing
6.6.1. Fecal Occult Blood Testing Market, 2018 – 2030 (USD Million)
6.7. Coagulation Testing
6.7.1. Coagulation Testing Market, 2018 – 2030 (USD Million)
6.8. Toxicology Testing
6.8.1. Toxicology Testing Market, 2018 – 2030 (USD Million)
6.9. Liquid Profile Testing
6.9.1. Liquid Profile Testing Market, 2018 – 2030 (USD Million)
6.10. Other Applications
6.10.1. Other Applications Market, 2018 – 2030 (USD Million)
Chapter 7. End-Use Business Analysis
7.1. Rapid Medical Diagnostic Kits Market: End-Use Movement Analysis
7.2. Hospitals & Clinics
7.2.1. Hospitals & Clinics Market, 2018 – 2030 (USD Million)
7.3. Homecare
7.3.1. Homecare Market, 2018 – 2030 (USD Million)
7.4. Diagnostic Laboratories
7.4.1. Diagnostic Laboratories Market, 2018 – 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Rapid Medical Diagnostic Kits Market Share By Region, 2022 & 2030
8.2. North America
8.2.1. SWOT Analysis
8.2.2. North America Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.2.3. U.S.
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. U.S. Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.2.4. Canada
8.2.4.1. Key Country Dynamics
8.2.4.2. Target Disease Prevalence
8.2.4.3. Competitive Scenario
8.2.4.4. Regulatory Framework
8.2.4.5. Canada Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.3. Europe
8.3.1. SWOT Analysis
8.3.2. Europe Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Germany Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.3.4. UK
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. UK Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.3.5. France
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. France Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Spain Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.3.7. Italy
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Italy Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.3.8. Denmark
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Denmark Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Sweden Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.3.10. Norway
8.3.10.1. Key Country Dynamics
8.3.10.2. Target Disease Prevalence
8.3.10.3. Competitive Scenario
8.3.10.4. Regulatory Framework
8.3.10.5. Norway Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.4. Asia Pacific
8.4.1. SWOT Analysis
8.4.2. Asia Pacific Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.4.3. Japan
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Japan Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.4.4. China
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. China Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.4.5. India
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. India Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.4.6. South Korea
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. South Korea Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.4.7. Australia
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Australia Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.4.8. Thailand
8.4.8.1. Key Country Dynamics
8.4.8.2. Target Disease Prevalence
8.4.8.3. Competitive Scenario
8.4.8.4. Regulatory Framework
8.4.8.5. Thailand Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.5. Latin America
8.5.1. SWOT Analysis
8.5.2. Latin America Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.5.3. Brazil
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Brazil Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.5.4. Mexico
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Mexico Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.5.5. Argentina
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Competitive Scenario
8.5.5.4. Regulatory Framework
8.5.5.5. Argentina Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.6. MEA
8.6.1. SWOT Analysis
8.6.2. MEA Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.6.3. South Africa
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. South Africa Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.6.4. Saudi Arabia
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Saudi Arabia Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.6.5. UAE
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. UAE Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
8.6.6. Kuwait
8.6.6.1. Key Country Dynamics
8.6.6.2. Target Disease Prevalence
8.6.6.3. Competitive Scenario
8.6.6.4. Regulatory Framework
8.6.6.5. Kuwait Rapid Medical Diagnostic Kits Market, 2018 – 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.3. Company Market Share Analysis, 2022
9.4. Company Profiles/Listing
9.4.1. ACON Laboratories, Inc.
9.4.1.1. Overview
9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Abbott Laboratories, Inc.
9.4.2.1. Overview
9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. Artron Laboratories, Inc.
9.4.3.1. Overview
9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Alfa Scientific Designs, Inc.
9.4.4.1. Overview
9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Becton
9.4.5.1. Overview
9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Dickinson & Co.
9.4.6.1. Overview
9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. BTNX, Inc.
9.4.7.1. Overview
9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. bioMerieux SA
9.4.8.1. Overview
9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. Cardinal Health
9.4.9.1. Overview
9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. Bio-Rad Laboratories, Inc.
9.4.10.1. Overview
9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives
9.4.11. Danaher Corporation
9.4.11.1. Overview
9.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.11.3. Product Benchmarking
9.4.11.4. Strategic Initiatives
9.4.12. Creative Diagnostics
9.4.12.1. Overview
9.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.12.3. Product Benchmarking
9.4.12.4. Strategic Initiatives
9.4.13. Meridian Bioscience
9.4.13.1. Overview
9.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.13.3. Product Benchmarking
9.4.13.4. Strategic Initiatives
9.4.14. F. Hoffmann La-Roche
9.4.14.1. Overview
9.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.14.3. Product Benchmarking
9.4.14.4. Strategic Initiatives
9.4.15. McKesson Medical-Surgical, Inc.
9.4.15.1. Overview
9.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.15.3. Product Benchmarking
9.4.15.4. Strategic Initiatives
9.4.16. Sight Diagnostics
9.4.16.1. Overview
9.4.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.16.3. Product Benchmarking
9.4.16.4. Strategic Initiatives
9.4.17. Trinity Biotech
9.4.17.1. Overview
9.4.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.17.3. Product Benchmarking
9.4.17.4. Strategic Initiatives
9.4.18. Zoetis
9.4.18.1. Overview
9.4.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.18.3. Product Benchmarking
9.4.18.4. Strategic Initiatives
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/